hepatology
FDA Approves Seladelpar for Primary Biliary Cholangitis
The FDA has granted accelerated approval to Livdelzi in combination with ursodeoxycholic acid for adults with PBC.
AUGUST 23, 2024
Shortened Protocol Can Prevent Infection in Recipients of HCV+ Organs
A shortened antiviral protocol adding ezetimibe can prevent infection in solid-organ recipients who receive ...
AUGUST 6, 2024
Low-Dose Aspirin Reduces Liver Fat in Patients With MASLD in Phase 2 Trial
A daily dose of aspirin led to a significant reduction in liver fat in patients with metabolic ...
AUGUST 2, 2024
Patient-Reported Outcomes Can Help Drive Drug Compliance
Incorporating patient-reported outcome measures such as disease symptoms and quality of life can increase ...
MAY 31, 2024
FDA Approves Maralixibat for Cholestatic Pruritus in PFIC
The FDA approved Livmarli for cholestatic pruritus in patients 5+ years with PFIC.
MARCH 17, 2024
FDA Approves Resmetirom, First Drug for MASH
The FDA granted accelerated approval to the first medication for the treatment of MASH, Rezdiffra.
MARCH 16, 2024
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 21, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
MARCH 16, 2022
Survey Documents Pandemic’s Toll On Liver Cancer Screening
Clinicians and patients faced significant disruption in liver cancer screening during the early COVID-19 pandemic, ...
NOVEMBER 10, 2021
